EMEA-001638-PIP01-14-M02
Table of contents
Key facts
Invented name |
Tecentriq
|
Active substance |
atezolizumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0207/2019
|
PIP number |
EMEA-001638-PIP01-14-M02
|
Pharmaceutical form(s) |
Concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Roche Registration GmbH
Tel. +41 616879411 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|
Compliance procedure number |
EMEA-C-001638-PIP01-14-M02
|
Compliance opinion date |
20/09/2019
|
Compliance outcome |
positive
|